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  ABSTRACT 
  Purpose      To evaluate the potential of etanercept versus 
sulfasalazine to reduce active inﬂ  ammatory lesions on 
whole-body MRI in active axial spondyloarthritis with a 
symptom duration of less than 5 years.   
  Methods      Patients were randomly assigned to etanercept 
(n=40) or sulfasalazine (n=36) treatment over 48 weeks. 
All patients showed active inﬂ  ammatory lesions (bone 
marrow oedema) on MRI in either the sacroiliac joints or 
the spine. MRI was performed at weeks 0, 24 and 48 and 
was scored for active inﬂ  ammatory lesions in sacroiliac 
joints and the spine including posterior segments and 
peripheral enthesitis by two radiologists, blinded for 
treatment arm and MRI time point.   
  Results      In the etanercept group, the reduction of the 
sacroiliac joint score from 7.7 at baseline to 2.0 at week 
48 was signiﬁ  cantly (p=0.02) larger compared with the 
sulfasalazine group from 5.4 at baseline to 3.5 at week 
48. A similar difference in the reduction of inﬂ  ammation 
was found in the spine from 2.2 to 1.0 in the etanercept 
group versus from 1.4 to 1.3 in the sulfasalazine 
group between baseline and week 48, respectively 
(p=0.01). The number of enthesitic sites also improved 
signiﬁ  cantly from 26 to 11 in the etanercept group 
versus 24 to 26 in the sulfasalazine group (p=0.04 for 
difference). 50% of patients reached clinical remission 
in the etanercept group versus 19% in the sulfasalazine 
group at week 48.   
  Conclusion      In patients with early axial spondyloarthritis 
active inﬂ  ammatory lesions detected by whole-body 
MRI improved signiﬁ  cantly more in etanercept versus 
sulfasalazine-treated patients. This effect correlated with 
a good clinical response in the etanercept group.             
  The treatment of ankylosing spondylitis (AS) 
with tumour necrosis factor (TNF) alpha block-
ing agents has been shown to be highly effec-
tive.    1     –      4    Shorter disease duration, together with 
young age, were among the best predictors for 
a major treatment response in several analy-
ses.    5     –      7    The new Assessment of SpondyloArthritis 
International Society (ASAS) criteria for axial 
spondyloarthritis were published recently cover-
ing both patients with and without radiographic 
sacroiliitis.    8    Active inﬂ  ammation of the sacroiliac 
joints as shown by MRI is an important part of 
these new criteria.    9    
  Until now two clinical studies with TNF block-
ers have been performed in patients with non-ra-
diographic axial spondyloarthritis showing a very 
good response in a high percentage of patients with 
a disease duration of less than 3 years.    7        10    
  MRI is currently the best imaging method for the 
detection of active inﬂ  ammation in the sacroiliac 
joints and the spine and an impressive reduction of 
such active inﬂ  ammation could be demonstrated 
in the past in several trials treating AS patients 
with TNF blockers,    10        11    but the treatment effect on 
other parts of the skeleton were not investigated 
by MRI. 
  Whole-body MRI may be an ideal tool to study 
not only the spine and sacroiliac joints but also the 
enthesial areas.    12     –      14    Two previous studies demon-
strated that whole-body MRI and conventional 
MRI showed a high correlation of active inﬂ  am-
mation both in the investigation of the sacroiliac 
joints    15    and spine.    16    
  In the current prospective randomised trial we 
investigated the effect of treatment with the TNF 
blocker etanercept in comparison with treatment 
with sulfasalazine on active bony inﬂ  ammation 
in the whole skeleton by whole-body MRI as the 
primary outcome parameter over 12 months in 
patients with early axial spondyloarthritis with a 
symptom duration of less than 5 years. 
  PATIENTS  AND  METHODS 
  Study  design 
  In this 48-week, randomised multicentre open-label 
trial (ClinicalTrials.gov identiﬁ  er  NCT00844142), 
76 patients with non-steroidal anti-inﬂ  ammatory 
drug (NSAID)-refractory axial spondyloarthritis 
were prospectively randomly assigned    17    to etan-
ercept 25 mg given twice weekly subcutaneously 
(n=40) or sulfasalazine 2–3 g per day given orally 
according to the local rheumatologist’s decision 
(n=36) for treatment over 48 weeks. In the case 
of intolerance to sulfasalazine patients could be 
switched to methotrexate (15–20 mg weekly by 
mouth). The study was approved by an indepen-
dent ethics committee.   
    Inclusion and exclusion criteria 
  Patients had to be 18–50 years of age and had to have 
a diagnosis of axial spondyloarthritis with a symp-
tom duration of less than 5 years. The diagnosis was 
made based on the presence of chronic low back 
pain with a duration of at least 3 months and onset 
at less than 45 years of age. All patients had to have 
active inﬂ  ammatory lesions (osteitis/bone marrow 
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0.96 for the sacroiliac joints. The ICC for change scores were 
0.86 (spine) and 0.94 (sacroiliac joints), respectively.     
  Statistical  analysis 
  Statistical analysis was performed as an intention-to-treat, 
last observation carried forward analysis. The non-parametric 
Mann–Whitney test was used to compare treatment groups at 
baseline. To compare changes in the sacroiliac joint and spine 
MRI scores between the treatment groups by taking the base-
line status into account a non-parametric analysis of covari-
ance (non-parametric ANCOVA) was used.    36    In a sensitivity 
analysis the possible inﬂ  uence of the diagnosis at baseline 
(non-radiographic axial spondyloarthritis vs AS), HLA-B27 
positivity, elevated CRP, clinical arthritis status on the pri-
mary outcome was examined by including those parameters 
as co-variables into the non-parametric ANCOVA model. One 
sulfasalazine patient with missing MRI data was excluded 
from the primary analysis. In 10 other patients (etanercept 
ﬁ  ve, sulfasalazine ﬁ  ve) with missing MRI data at week 48 the 
last observation carried forward method was applied to com-
plete the data for the primary analysis. The non-parametric 
ANCOVA or, if appropriate, the usual parametric ANCOVA 
with the baseline value as a co-variable was applied to analyse 
secondary outcomes. 
  Furthermore, the parametric ANCOVA was used to inves-
tigate the correlation between changes in clinical parameters 
(BASDAI, BASFI, CRP, enthesitis count at week 48) and changes 
in MRI score (spine, sacroiliac joints, enthesitis) after adjustment 
for treatment and the baseline status in the corresponding clinical 
and MRI parameter. p Values less than 0.05 were considered sta-
tistically signiﬁ  cant. The Holm procedure was applied to adjust 
for repeated signiﬁ  cance testing of the primary outcome.    37        
  RESULTS 
  Baseline  characteristics 
  Of the 76 patients fulﬁ  lling the inclusion criteria, 40 were ran-
domly assigned to receive etanercept and 36 sulfasalazine. The 
mean dose of sulfasalazine was 1688 mg (n=32) at week 24 
and 1650 mg (n=30) at week 48; four patients were switched 
to methotrexate (15.0 mg weekly for each patient) because of 
intolerance to sulfasalazine. Patients’ characteristics were simi-
lar, with no statistical difference between the etanercept and the 
sulfasalazine group (  table 1  –  3  ).   
  All patients were active as shown by clinical parameters 
and positive MRI (  table 2  ). At baseline, 94.6% of the patients 
showed active inﬂ   ammatory lesions in the sacroiliac joints, 
47.3% in the spine, but only 5.4% in the spine but not in the 
sacroiliac joints.     
    Primary and secondary MRI outcome parameters 
  In the etanercept group, there was a clear reduction of the 
mean sacroiliac joint score from 7.8 at baseline to 2.4 at week 
48 (  table   2  ). After adjusting for the non-signiﬁ  cantly  differ-
ent baseline MRI score, this reduction remained signiﬁ  cantly 
(p=0.02) larger compared with the sulfasalazine group: 5.4 and 
3.5, respectively (  table 2  ). Inﬂ  ammation was thus reduced after 
1 year of treatment by 69.2% in the etanercept group in com-
parison to 35.2% in the sulfasalazine group. The same was true 
when the reduction of inﬂ  ammation in the spine was compared 
between the two groups (p=0.01) (  table 2  ). The results of the 
primary outcome remained signiﬁ  cant after taking the presence 
of two co-primary endpoints (MRI sacroiliac joint and spine 
scores) into account. In the sensitivity analysis similar signiﬁ  cant 
oedema) on whole-body MRI in either the sacroiliac joints or 
the spine plus three out of the following criteria: (1) inﬂ  amma-
tory back pain;    18    (2) good or very good response to NSAID; (3) 
one or more of the extraspinal manifestations such as uveitis, 
peripheral arthritis, enthesitis; (4) HLA-B27 positivity; (5) a posi-
tive family history for spondyloarthritis.    8        9       19       20    Retrospectively, 
all patients fulﬁ  lled the recently published ASAS classiﬁ  cation 
criteria for axial spondyloarthritis.    8    All patients had to have a 
  Bath ankylosing spondylitis disease activity index   (BASDAI) of 
4 or greater    21    and a back pain score (BASDAI question 2) of 4 
or greater, despite treatment with NSAID and had undergone 
investigation with the same whole-body MRI at weeks 0, 24 
and 48. Treatment with disease-modifying antirheumatic drugs 
or 7.5 mg/day or more of prednisone (or equivalent) had to be 
discontinued at least 4 weeks before initiation of the study.   
  Outcome  assessments 
  The primary endpoint of this study was the change of active 
inﬂ  ammatory lesions in the sacroiliac joints and spine as detected 
by MRI at 48 weeks. Secondary endpoints were the reduction 
of active inﬂ  ammatory lesions on the posterior elements of the 
spine and a reduction of peripheral enthesitis on MRI, and the 
following clinical endpoints: BASDAI50, ASAS20 and 40 and 
ASAS partial remission.    22         23    
  Other clinical and laboratory outcome assessments    24    included 
BASDAI, Bath ankylosing spondylitis functional index (BASFI),    25    
Bath ankylosing spondylitis metrology index (BASMI) on an 
11-point answer scale,    26    a modiﬁ  ed enthesitis Maastricht anky-
losing spondylitis enthesitis score    27      with an additional two sites 
at each knee (17 sites), a swollen joints count with 64 joints,    28    
patient’s and physician’s global assessments of disease activity 
and C-reactive protein (CRP).    24         29     –      31      
  Whole-body  MRI 
  Whole-body MRI was performed on a 1.5 T scanner (Avanto 
TIM, Siemens, Germany) according to a previously described 
protocol.    12        14    Due to the conﬁ  guration of the coils, elbow, wrist, 
ﬁ  nger and toe joints could not be depicted. 
    Scoring of whole-body MRI 
  MRI were scored for active inﬂ  ammatory lesions by two radi-
ologists, blinded for treatment arm and MRI time point. 
  Active inﬂ   ammatory lesions of the sacroiliac joints were 
scored according to a slightly modiﬁ   ed previously described 
scoring method,    32    with each sacroiliac joint divided into four 
quadrants. Each quadrant was scored for osteitis/bone marrow 
oedema as follows: 0, absent (no osteitis); 1, less than 33% of 
quadrant area; 2, 33% or more to less than 66% of quadrant 
area; 3, 66% or more of quadrant area with a maximum score 
of 24. For the entire spine with 23 vertebral units, a recently 
described    33     –      35    scoring system was used to score active inﬂ  am-
mation, resulting in a score between 0 and 69, grade 0–3 per ver-
tebral unit. The sacroiliac joint and the spine MRI scores were 
calculated by using the mean values of both scorers. Scoring of 
the posterior elements included assessment for active inﬂ  amma-
tory lesions of the facet joints, the costovertebral joints and the 
spinous processes in each vertebral unit. Posterior segments and 
peripheral enthesitis (active osteitis) were scored in consensus 
between both scorers with a ‘yes’ or ‘no’ answer for altogether 
27 enthesitic sites of the non-axial skeleton (for further details 
see Althoff   et al  , manuscript in preparation). 
  The intraclass correlation coefﬁ  cient (ICC) at baseline was 
0.93 for assessing active inﬂ  ammatory lesions of the spine and 
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week 48 1.9; sulfasalazine baseline 3.7, week 48 3.2), resulting 
in a reduction of 55% in the etanercept group versus 14% in the 
sulfasalazine group (p=0.03). 
  At week 48 six patients from the etanercept compared with 
two patients from the sulfasalazine treatment group became 
free of any active inﬂ  ammatory lesions on MRI at any site in 
the skeleton including the spine, sacroiliac joints, entheses and 
posterior elements. 
results were found for the primary endpoints. Figure 1 shows 
MRI examples for the reduction of active inﬂ  ammatory lesions 
in the sacroiliac joints, the spine and enthesitis. The improve-
ment on the patient level is shown in the probability plots in 
  ﬁ  gure 2  .   
  When analysing only patients with at least one active spinal 
lesion (n=35), the difference in the improvement of the MRI 
spine score was even more remarkable (etanercept baseline 4.2, 
  Table  1         Baseline characteristics of study patients by treatment group   
 Characteristic   Etanercept  group    (n=40)   Sulfasalazine  group    (n=36)   All  patients    (n=76) 
Age in years, mean (±SD) 34.5 (8.6) 32.8 (8.4) 33.7 (8.5)
Disease duration (back pain duration) in years, mean (±SD)   2.6 (1.7)   3.0 (1.8)   2.9 (1.7)
Male patients, n (%) 23 (57.5) 21 (58.3) 44 (57.9)
HLA-B27 positive, n (%) 34 (85) 28 (77.8) 62 (81.6)
Elevated CRP (CRP >5 mg/l), n (%) 24 (60.0) 16 (44.4) 40 (52.6)
Clinical arthritis, n (%) 15 (37.5) 18 (50.0) 33 (43.4)
Clinical enthesitis, n (%) 25 (62.5) 24 (66.7) 49 (64.5)
Fulﬁ  lled New York criteria, n (%)   20   20 (50) 19 (52.8) 39 (51.3)
      For further baseline data see   tables 2   and   3  . 
  CRP, C-reactive protein (reference range <5mg/l).     
  Table  2         MRI scores of sacroiliac joints, spine, enthesitis and posterior segments of the spine at baseline, week 24 and at week 48 in the etanercept 
versus sulfasalazine treatment group   
 Parameters  assessed   Time    Etanercept group (n=40)    Sulfasalazine group (n=36)   p  Value* 
MRI sacroiliac joint score (0–24), mean (SD) Baseline† 7.8 (6.3) 5.4 (5.1)  
Week 24 3.1 (3.6) 3.7 (3.2) 0.006
Week 48 2.4 (3.2) 3.5 (3.8) 0.02
MRI spine score (0–69), mean (SD) Baseline† 2.3 (3.5) 1.4 (3.1)  
Week 24 1.4 (3.1) 1.5 (3.1) 0.03
Week 48 1.0 (2.1) 1.3 (2.9) 0.01
MRI enthesitis‡ Baseline† 26 sites (in 15 patients) 24 sites (in 16 patients)  
Week 24 22 sites (in 12 patients) 23 sites (in 14 patients) 0.67
Week 48 11 sites (in 11 patients) 26 sites (in 14 patients) 0.04
MRI posterior segments of the spine Baseline† 37 sites (in 9 patients) 18 sites (in 4 patients)  
Week 24 30 sites (in 4 patients) 13 sites (in 2 patients) 0.78
Week 48 26 sites (in 2 patients) 13 sites (in 1 patient) 0.92
      *p Values for comparison of changes in the MRI scores between both groups by analysis of covariance. 
  †No signiﬁ  cant differences at baseline between etanercept and sulfasalazine: sacroiliac joints (p=0.06), spine (p=0.09), enthesitis (p=0.50), posterior segments (p=0.25). 
  ‡Only active osteitis (hyperintense bone signal in the STIR sequence) was scored as enthesitis.     
A CDE
F B
  Figure  1         Examples for MRI before and after 48 weeks of treatment with etanercept: (a) sacroiliac joints: baseline MRI, sacroiliac joint score 15.5 
(A), week 48 MRI, sacroiliac joint score 0 (B); (b) spine, baseline MRI spine score 11.5 (C), week 48 MRI spine score 1 (D); (c) enthesitis of lateral 
condyle of femur of right knee (dorsal view), MRI baseline with enthesitis (E), week 48 without enthesitis (F).         
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whole-body MRI, a signiﬁ  cant difference between the groups 
(p=0.03). 
  When the whole group was separated into patients with AS 
and patients with non-radiographic axial spondyloarthritis there 
were no clear differences for the reduction in MRI scores and 
clinical parameters (data not shown). 
  Dropouts 
  Seven dropouts were noted before week 24, another three before 
week 48, among them ﬁ  ve each in the etanercept group (two 
wishes for pregnancy, three lost to follow-up), and the sulfasala-
zine group (two lost to follow-up, one discontinuation because 
of side-effects and lack of efﬁ  cacy and one patient because of 
new lymphoma).   
  Safety 
  Three hundred and twenty-one adverse events (AE) occurring in 
71 patients were reported (167 AE in 39 etanercept patients and 
154 AE in 32 sulfasalazine patients). Infections of the respira-
tory tract were the most frequently reported AE. In total, there 
were three serious AE in the etanercept group and seven in the 
sulfasalazine group. Among the serious AE only three were 
regarded as potentially treatment related (one etanercept and 
two sulfasalazine patients).       
  DISCUSSION 
  In the present study we performed the most comprehensive 
analysis so far of the response of active inﬂ  ammation, as shown 
by MRI, to treatment with a TNF blocker in comparison with 
  As shown in   table 2  , active inﬂ  ammation in the posterior 
  segments of the spine was present in 13 patients (17.1%). There 
was a reduction from 37 to 26 sites in the etanercept group 
between baseline and week 48 versus from 18 to 13 sites in 
the sulfasalazine group; however, this difference was not sig-
niﬁ  cant (  table 2  ). Enthesitis was present in 31 patients (40.8%) 
at baseline. The number of enthesitic sites was reduced sig-
niﬁ  cantly by 58% at week 48 in the etanercept group, whereas 
there was no reduction in the sulfasalazine group (p=0.04 for 
the difference between the two groups;   table 2  ).  
    Secondary clinical outcome parameters 
  The analysis of the clinical efﬁ  cacy data showed a statistically 
signiﬁ  cant reduction of all analysed variables in the etanercept 
in comparison with the sulfasalazine treatment group, except for 
the BASMI, swollen joints, clinical enthesitis and CRP (  table 3   
and   ﬁ  gure 3  ).   
  There was a signiﬁ   cant correlation between changes in 
BASDAI and BASFI and changes in the MRI sacroiliac joint 
scores (p values were 0.04 and 0.0069, respectively), but not for 
CRP. However, there was no signiﬁ  cant correlation between 
MRI enthesitis and MRI spine scores and clinical parameters. 
  Of the six patients who became completely free of inﬂ  am-
mation both in the sacroiliac joints and spine in the etanercept 
group, all patients were also in clinical remission according to 
the ASAS criteria (15.4% of the whole etanercept-group). In 
contrast, none of the two patients reaching remission in the sul-
fasalazine group (0%) was free of inﬂ  ammation as shown by 
  Table  3         Efﬁ  cacy data at baseline, week 24 and at week 48 in the etanercept versus sulfasalazine treatment group   
 Parameters  assessed   Time    Etanercept group (n=40)   Sulfasalazine  group    (n=36)   p  Value* 
BASDAI (0–10), mean (±SD) Baseline† 5.5 (1.3) 6.0 (1.2)  
Week 24 2.6 (2.3) 4.4 (2.2) 0.002
Week 48 2.5 (2.0) 4.4 (2.4) 0.001
BASFI (0–10), mean (±SD) Baseline† 4.3 (2.3) 4.3 (1.8)  
Week 24 1.9 (2.2) 3.1 (2.2) 0.005
Week 48 2.0 (2.1) 3.3 (2.2) 0.001
Patient global (0–10), mean (±SD) Baseline† 6.7 (2.1) 7.1 (1.6)  
Week 24 2.6 (2.6) 5.1 (2.5) <0.001
Week 48 2.6 (2.2) 4.9 (3.0) <0.001
Physician global (0–10), mean (±SD) Baseline† 6.4 (1.2) 6.1 (1.5)  
Week 24 1.8 (1.9) 3.8 (2.5) <0.001
Week 48 1.8 (1.8) 4.1 (2.9) <0.001
Joint count (0–64), mean (±SD) Baseline† 2.3 (5.8) 1.3 (1.7)  
Week 24 0.3 (1.3) 0.4 (2.0) 0.70
Week 48 0.2 (0.7) 0.3 (1.5) 0.48
Enthesitis score (0–17), mean (±SD) Baseline† 4.4 (4.6) 3.4 (3.4)  
Week 24 1.6 (4.1) 2.6 (3.6) 0.01
Week 48 1.8 (4.2) 1.4 (2.9) 0.70
BASMI (0–10), mean (±SD) Baseline† 1.9 (1.7) 1.7 (1.4)  
Week 24 1.7 (1.6) 1.9 (1.6) 0.28
Week 48 1.6 (1.8) 1.9 (1.7) 0.32
EQ-5D (0–1), mean (±SD) Baseline† 0.6 (0.3) 0.6 (0.3)  
Week 24 0.9 (0.2) 0.7 (0.2) 0.01
Week 48 0.8 (0.2) 0.7 (0.3) 0.047
AS-QoL (0–18), mean (±SD) Baseline† 9.7 (4.5) 9.3 (3.6)  
Week 24 4.1 (4.3) 7.4 (5.0) <0.001
Week 48 4.4 (4.8) 7.5 (5.4) <0.001
CRP (ref 5 mg/l), mean (±SD) Baseline† 11.9 (13.2) 10.6 (14.9)  
Week 24 4.2 (3.5) 8.5 (11.8) 0.07
Week 48 4.3 (3.7) 8.7 (12.5) 0.13
      *p Values for comparison of changes in the parameters between both groups by analysis of covariance. 
  †No signiﬁ  cant differences at baseline between etanercept and sulfasalazine. Every mean value refers to the complete intention-to-treat population (etanercept, n=40; sulfasalazine, 
n=36). 
  ASQoL, ankylosing spondylitis quality of life questionnaire; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis disease functional index; 
BASMI, Bath ankylosing spondylitis metrology index; CRP, C-reactive protein (reference range <5mg/l); EQ-5D, EuroQoL index.     
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  The current study can best be compared with an inﬂ  iximab 
trial in axial spondyloarthritis patients with a symptom dura-
tion of less than 3 years, which also showed a good reduction of 
active inﬂ  ammation on MRI.    10    
  In the study mentioned above,    10    an improvement in the spi-
nal inﬂ  ammation was also reported, but only the presence or 
absence of inﬂ  ammation per spinal area was scored without fur-
ther quantiﬁ  cation and without differentiation of inﬂ  ammation 
found in the vertebral body and the posterior segment. 
  There was no clear difference between the two treatment 
groups in the reduction of inﬂ  ammation present in the poste-
rior segments of the spine (  table 2  ) in the present study, which 
may be due to the small percentage of patients in whom the 
posterior segment was involved. The 17% positive patients 
at baseline in our study are different from previous reports, 
which found inﬂ  ammation at this site in a higher percentage 
of patients.    38        39    
  So far only one whole-body MRI study has tried to score inﬂ  am-
matory sites other than spine and sacroiliac joints in patients with 
axial spondyloarthritis.    40    In that study only the shoulder and pel-
vic girdles and the anterior chest wall were included, whereas 
the lower extremities were left out, although they are frequently 
affected in spondyloarthritis. Therefore, again the current study 
is the ﬁ  rst one to include these sites and, even more importantly, 
to investigate inﬂ  ammation in a blinded controlled fashion over 1 
year of treatment with etanercept compared with sulfasalazine. 
  Enthesitis by MRI was found in 40.8% of patients, a frequency 
lower than clinically evident enthesitis (  table 1  ). Most interest-
ingly, the number of enthesitic sites was reduced by nearly 58% 
(  table 2  ) at week 48 in the etanercept group, a percentage similar to 
the reduction in inﬂ  ammation observed in the sacroiliac joints and 
spine. On the other hand, there was no reduction in the sulfasala-
zine group, supporting the view that inﬂ  ammation in sacroiliac 
joints, spine and enthesitic sites has a very   similar immunopathol-
ogy and response to treatment.    41        42    Until now only one other con-
trolled study showed a favourable effect of a TNF blocker, in this 
case also etanercept, on enthesitis as shown by MRI.    43    
sulfasalazine treatment over 1 year in patients with axial spondy-
loarthritis. In these patients with a symptom duration of less than 
5 years most inﬂ  ammation was found in the sacroiliac joints in 
comparison with the spine or other extraspinal sites. Accordingly, a 
larger improvement in sacroiliac joint inﬂ  ammation was observed 
compared with spinal inﬂ  ammation when patients were treated 
with etanercept (  table 2  ), but the differences compared with the 
sulfasalazine group were clearly signiﬁ  cant both for the sacroiliac 
joint and spine at week 24 and at week 48. 
  Figure  3         Response of the Assessment of SpondyloArthritis 
International Society (ASAS) criteria for 20% improvement in disease 
activity (ASAS20), the ASAS40, the ASAS criteria for partial remission 
(Pr), and the Bath ankylosing spondylitis disease activity index criteria 
for 50% improvement (BASDAI50) in week 48 after treatment with 
etanercept (n=40) or sulfasalazine (n=36) in patients with active 
axial spondyloarthritis. Signiﬁ  cantly more patients from the etanercept 
group compared with the sulfasalazine group reached ASAS20 (85%, 
95% CI 70.7% to 93.3% vs 42%, 95% CI 25.5% to 59.2%; p=0.001), 
ASAS 40 (70%, 95% CI 54.2% to 83.4% vs 31%, 95% CI 17.7% to 46.6%; 
p=0.001), ASAS partial remission (50%, 95% CI 34.4% to 65.6% vs 19%, 
95% CI 8.5% to 35.5%; p=0.006) and BASDAI50 (65%, 95% CI 48.3% to 
78.8% vs 28%, 95% CI 14.2% to 43.6%; p=0.001).       
  Figure  2         Cumulative probability of changes in MRI activity scores of the sacroiliac (SI) joints (A) and the spine (B) from baseline to week 48 in 
the etanercept and sulfasalazine treatment groups. Each data point in A and B represents an individual patient. For sacroiliac joint scores, double 
probability plots for the etanercept group (A1) and the sulfasalazine group (A2) are shown, with the baseline MRI activity score for each patient 
plotted above the corresponding change scores from baseline to week 48.       
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  In conclusion, in this early axial spondyloarthritis trial over 
1 year, etanercept, in comparison with sulfasalazine, improved 
bony inﬂ  ammation at different sites of the skeleton considerably, 
in parallel to an observed clinical improvement. These results 
suggest that TNF blockers in axial spondyloarthritis patients are 
effective when patients are treated early.         
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